Immunic AG is a start-up biotech company founded in April 2016 and focused on the development of immune modulators to block TH17- and TH1-mediated immune and autoimmune responses. The company’s two development programs include orally available, small molecule inhibitors of DHODH (IMU-838 program) and RORyt (IMU-366 program) relevant to diseases such as Crohn’s disease and psoriasis. The final aim is to develop these drug candidates to clinical proof of concept. Immunic, with headquarters in Planegg-Martinsried near Munich, Germany, is privately held and supported by several renowned sector investors.
Dr. Manfred Groeppel
While working three years at the Research Center Siemens, Dr. Gröppel received his Doctorate in chemistry from the Institute of Organic Chemistry, University Erlangen-Nürnberg, Germany.
Prior to joining 4SC, Manfred hold various positions at Tripos Inc., covering business development activities in Central and South Europe, Scandinavia and Israel.
In his role as Head of Business Development, Manfred managed worldwide business development activities for 4SC since 2001.
Manfred is an experienced business development professional with a track record of successful licensing transactions in the healthcare industry worldwide (EU, USA, Japan). More than 18 years of BD/L leadership experience with a strong scientific background and sound knowledge in drug discovery, product development, manufacturing processes, CMC, patents, clinical trial design, regulatory and project valuation.
Manfred has established a worldwide network including USA, Japan, Korea and China and was involved in several deals worth more than $500mio including Menarini, Yakult Honsha, Link Health, Nycomed , Serono, Schwarz Pharma, Sanofi-Aventis, Boehringer Ingelheim, Schering, Astra Zeneca, Recordati and Esteve.
Amongst other successful transactions, major achievements include:
– Out-licensing of APAC rights of Resminostat (phase II) to Menarini in a deal worth up to €95m plus double-digit royalties
– Out-licensing of Japanese rights of Resminostat (phase II) to Yakult Honsha in deal worth more than $192m plus royalties, featured on the front page of Bioworld, April 2011
– Successfully in-licensed 8 projects, clinical and pre-clinical stage, for €14m in a one-time payment without further milestones and royalties
– In charge of finding a new home for an innovative project into a spin-off company in the USA.
Manfred has been Invited speaker at several national and international conferences and is owner of several patents and co-author of scientific publications.
Finally, Manfred has been part of the development team since 2002 and served as project leader for the autoimmune project IMU-838.
Dr. Andreas Muehler
Dr. Andreas Mühler received his medical degree (MD) from Humboldt-University in Berlin (Germany) and an MBA degree from Duke University. After a short period in clinical work, Andreas has worked within the pharmaceutical industry since 1992, most of it in the US, with leadership positions in preclinical and clinical development, business development & licensing and marketing. During this period, Andreas was involved in several clinical programs and regulatory submissions (IND, NDA) as well as several large licensing deals.
Since 2003, Andreas developed and managed multiple medical companies in the US. Among them were 3TP LLC d/b/a CAD Sciences (White Plains, NY), a medical software company developing an imaging solution for early detection of breast and prostate cancer, which was subsequently sold to iCAD Medical in 2008. Another startup was Cellectar Inc. (Madison, WI), a biotech company developing new cancer therapeutics and cancer imaging agents, in which Andreas managed the initial development of the lead compound until IND filing.
Andreas was also President & CEO of MicroMRI Inc (Langhorne, PA), a medical device company developing solutions for improved osteoporosis diagnosis and therapy monitoring based on bone micro-architecture. He has been on the Board of Directors of multiple small medical technology companies.
After moving to Munich in 2009, Andreas became Managing Director of the small healthcare private equity fund Palladius Healthcare GmbH (Munich, Germany) which acquired distressed medical technology companies. As part of this fund, Andreas was involved in the management of portfolio companies.
Thereafter, Andreas worked as interim manager and has been doing multiple interim management projects for pharmaceutical and medical device companies. Most of these assignment involved managing large clinical trials in the oncology area. Additionally, Andreas was also closely involved in the launch of several major pharmaceuticals in Germany, among them Brentuximabvedotin (for treatment of Hodgkin lymphoma and some NHL), Vedolizumab (an antibody for treatment of inflammatory bowel disease) and an oral budesonide as treatment for ulcerative colitis.